CADL

Candel Therapeutics shares fell even after the company reported encouraging data for its prostate cancer drug candidate. Retail investors are pushing back against the drop, with many calling the stock 'clearly a buy and hold' and arguing the market is overlooking the positive clinical results. The disconnect between the upbeat data and the falling share price is fueling debate among traders about the biotech's prospects.